Cancer Care Ontario | Cancer Care Ontario

encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Cetuximab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

encorafenib,

cetuximab

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Apr 2024

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2020

Status: Current
ID: PET 2020-1
Version: N/A

Nov 2020

Guidelines and Advice

Enhancing Clinical Cancer Genetic Service Delivery in Ontario - Recommendations for a New Model of Care

Status: Current
Version: 1.0

Dec 2020

Drug

enasidenib

Other Name(s): Idhifa®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jul 2023

Guidelines and Advice

Virtual Care in Patients with Cancer: A Systematic Review

Status: Current
ID: ES 30-1

Mar 2021

Regimen

VENE(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

venetoclax - Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

venetoclax

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

May 2024

Guidelines and Advice